Single-Agent Gemcitabine in Heavily Pretreated Ovarian Cancer: Experience from a Canadian Tertiary Centre

Key Points

• Significant responses to gemcitabine were observed in patients with heavily pretended ovarian cancer, indicating potential efficacy.
• In this analysis, the objective response rate reached 30% in a cohort treated with gemcitabine after extensive previous therapies.
• Observational analysis focusing on gemcitabine's role shows promise, despite challenges posed by pretreatment history.
• These findings may inform future treatment strategies for patients with limited options due to prior therapies.